Ger‐Jan Sanderink

The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers

Ger‐Jan Sanderink, A. Le Liboux, Navin Jariwala et al. · Clinical Pharmacology & Therapeutics · 2002 · 184 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +13

Dosage Adjustment and Pharmacokinetic Profile of Irinotecan in Cancer Patients With Hepatic Dysfunction

Éric Raymond, Valérie Boige, Sandrine Faivre et al. · Journal of Clinical Oncology · 2002 · 118 citations

Pharmacy, Oncology, Pharmacology +17

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Otto Soepenberg, Herlinde Dumez, Jaap Verweij et al. · Clinical Cancer Research · 2005 · 85 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non‐ST‐segment elevation myocardial infarction

René Bruno, P. Baille, Sylvie Retout et al. · British Journal of Clinical Pharmacology · 2003 · 44 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Phase I study of an oral formulation of irinotecan administered daily for 14�days every 3�weeks in patients with advanced solid tumours

Nadja E. Schoemaker, I. E. L. M. Kuppens, W.W. ten Bokkel Huinink et al. · Cancer Chemotherapy and Pharmacology · 2004 · 29 citations

Medicine, Oncology, Pharmacology +14